Design and Discovery of Resorbable Polymers for Coronary Stents

Similar documents
Evolution of Intravascular Technology for Coronary Artery Disease Treatment

Company Update. 28 May REVA Medical, Inc.

For personal use only

Bioresorbable Scaffold Program Update. Alexandre Abizaid, MD, PhD, FACC Instituto Dante Pazzanese de Cardiologia Sao Paulo, Brazil

Tyrocore: a proprietary polymer uniquely designed for vascular scaffolds

Testimony of Joachim Kohn, Ph.D Board of Governors Professor of Chemistry and Chemical Biology Rutgers, the State University of New Jersey.

REVA s Bioresorbable Scaffold Program Update. Alexandre Abizaid, MD, PhD, FACC Instituto Dante Pazzanese de Cardiologia Sao Paulo, Brazil

The Next Generation of Stents for the Lower Extremity: What s on the Horizon?

Bioresorbable Stent Implantation for Tibial Disease

Bioabsorbable Stents. The Ideal Scaffold properties and kinetics. Jonathan Hill King s College Hospital King s Health Partners

For personal use only

President St. Joseph s Heart and Vascular Institute Professor of Medicine Emeritus Emory University

Dr. Alexandre Abizaid Instituto Dante Pazzanese de Cardiologia Sao Paulo, Brazil

Abbott Vascular Inc. - Product Pipeline Analysis, 2016 Update

Fantom: A Radio-Opaque Stent-Like BRS With Improved Expansion Characteristics

Empowering innovation.

REVA Medical. Corporate Presentation November REVA Medical REVA Medical CC Rev. C

Nanodiamond-Based Therapeutic Delivery Films For the Treatment of Cancer and Inflammation

Comparison of SynBiosys Urethane-linked Multi-block Copolymer and PLGA Coatings

REVA Medical. Corporate Presentation January REVA Medical CC Rev. D REVA Medical.

Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.

Tissue- Biomaterial Interactions

Rationale and Design of the Prospective, Multicenter, Randomized Trial of 2 nd Generation BuMA DES in Europe

Novel BioResorbable Vascular Platforms from India

Immunology 101: Implications for Medical Device Failure. Joshua B. Slee, PhD Assistant Professor of Biology

UConn BMES Meeting #2 (9/28) T R A C K P R E S E N T A T I O N S

Biomaterials. Third Edition

W BIOENGINEERING. Nanomaterials Applications in Biology and Medicine. Topics:

Symposium Biotronik High-Tech DRug Eluting Absorbable Metal Stent: dreaming the future! Didier Tchétché. Clinique Pasteur.

Applications in Cardiology Hollow Fiber Membranes and Applications

Polymeric hydrogels are of special importance in polymeric biomaterials because of

REVA Medical. Corporate Presentation November REVA Medical REVA Medical CC Rev. B

Bioabsorbable Stents - Medical Devices Pipeline Assessment, 2015

Pittsburgh Tissue Engineering Initiative Annual Progress Report: 2010 Formula Grant

Cre8 TM BTK polymer-free DES technology: the Activ8 clinical trial

Course Syllabus. BMEN 4360: Biomaterials and Medical Devices Fall Course Information

Course Syllabus. BMEN 4360: Biomaterials and Medical Devices Fall Course Information

Approaching Commercialization

White Paper: Designing Functional Fabrics for Today s Heart Valves and Beyond

For personal use only

Bioabsorbable metal stents: properties, modeling and open questions

Nanoscale Phase Separation and Water Uptake in Polymeric Biomaterials

Effect of CNTs on Shape memory properties of PLLA/PCL blends

Biocompatibility and War and Peace

SYNERGYTM. Everolimus-Eluting Platinum Chromium Coronary Stent System

For personal use only

Endovascular Device Testing A Survey of Requirements for Product Validation

Biosensors International Group. 28 th Annual J.P. Morgan Healthcare Conference January 2010

The Importance of Vessel Preparation

Metallic Implants In Biomedical Engineering. Kerstin Tillmann March 2011

ISO Cardiovascular implants Endovascular devices Part 2: Vascular stents Part 2: Vascular stent

Engage with us on Twitter: #Molecule2Miracle

Patrick W. Serruys, MD, PhD

Negatively charged microspheres provide an additional surface for cell attachment leading to proliferation, tissue regeneration and wound healing

Marcia L. Zucker, Ph.D. ZIVD LLC

Cell-Environment Interactions. Chieh-Chun Chen

Surface Characterization of Biomaterials

The role of polymers in drug-eluting stents

S.M.A.R.T. Our inspiration came right from the source. Feeling is believing. S.M.A.R.T. Flex Vascular Stent System. LinkedIn page

Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2017

For personal use only

STUDY OF STENT DEFORMATION AND STRESS DEVELOPED AT DIFFERENT STENT DEPLOYMENT PRESSURES

Reliability into. for Biomedical. Devices: Finite Elelment Analyses. Applications CAE Associates

The University of North Texas Department of Materials Science & Engineering

Present and future of regenerative medicine. Liver Transplantation

BFF1113 Engineering Materials DR. NOOR MAZNI ISMAIL FACULTY OF MANUFACTURING ENGINEERING

Synthetic Viruses Targeting Cancer

ISO INTERNATIONAL STANDARD. Cardiovascular implants Endovascular devices Part 2: Vascular stents

Introduction to Drug Design and Discovery

Dr. Alexandre Abizaid Instituto Dante Pazzanese de Cardiologia Sao Paulo, Brazil. On behalf of the FANTOM II investigators

Additive manufacturing for long term implants. Presentation Content

Artificial blood vessels

PIB for Fun and Profit

Coagulation Mechanisms Dr. Nervana Bayoumy

LC/MS. Why is it the fastest growing analytical technique?

Combinatorial Polymer Libraries to Elucidate Dendritic Cell Phenotype-Material Property Relationships

For personal use only

The Effects of Scaffold Rigidity on Retinal Pigment Epithelial Cells. Corina White Symposium on Biomaterials Science 24 October 2016

Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2016

DESIGN, FUNCTION AND USES. R. James Christie Oct. 4, 2008 Utsunomiya Girls High School

Tissue Engineering: The art of growing body parts. Robby Bowles, Ph.D Cornell University

Biomaterial Surfaces and Biointerfaces Surface Science II

colorimetric sandwich ELISA kit datasheet

Drug Delivery from Cardiovascular Stents, In Pursuit of a Non-Polymeric Approach

Marcia L. Zucker, Ph.D. ZIVD LLC

Interventional Cardiology Advisory Group Meeting held 17 February (minutes for web publishing)

Integration of Combinatorial Synthesis, Rapid Screening, and Computational Modeling in Biomaterials Development

BEH.462/3.962J Molecular Principles of Biomaterials Spring 2003

Active biomaterials/scaffolds for stem cell-based soft tissue engineering (in a nutshell )

Drug /Device Combinations: The Convergence of Pharmaceutical and Biomaterial Science

Introduction to Biomaterials

Contrarian Play in Cardiology:

Cellular repair of damaged organs. Repopulating scaffoldings in kidney and liver

Cardiovascular stents: overview, evolution, and next generation

ON THE DESIGN OF A BIODEGRADABLE POC-HA POLYMERIC CARDIOVASCULAR STENT JOONAS ILMARI PONKALA. Presented to the Faculty of the Graduate School of

List of E-journals Subscribed for the year 2016 (January to December) Pharmacy Faculty Sl. No.

Raman Spectroscopy for Pharmaceutical Applications

Degradation rate. of bioresorbable materials. Prediction and evaluation. Edited by Fraser Buchanan. Woodhead publishing limited.

The Balance of Safety, Efficacy, and Reasonable Assurance in DES An FDA View

Tissue Engineered Medical Products

Transcription:

Design and Discovery of Resorbable Polymers for Coronary Stents Presented at Polymers in Medicine and Biology 2013 Joachim Kohn Director New Jersey Center for Biomaterials Rutgers University Piscataway, New Jersey

Overview This lecture covers the early history of stent development up to the first deployable prototype, focusing on polymer design principles The following lecture by Dr Zeltinger focuses on the clinical experience and recent data Disclosure: Joachim Kohn is a consultant for REVA and has a financial interest in REVA

Percutaneous Transluminal Coronary Angioplasty (PTCA)

Resorbable or permanent? The very early thoughts about preventing restenosis after angioplasty indicated that a temporary support device was needed to keep the injured blood vessel open The Kohn Lab submits a research proposal on developing new polymers for resorbable stents in 1988 (and doesn t get funded) For lack of any other options, the first clinically used stents were permanently implanted metal stents.

Progression of Stent Development Metal stents 93 Palmaz-Schatz stent FDA approved for coronary use Antiplatelet or anticoagulant coated metal stents 00 Phosphorylcholine coated and heparin coated stents FDA approved Resorbable polymeric stents 00 Tamai et al. first to implant resorbable PLLA coronary stents in humans using a heated balloon technique Anti-restenosis drug-eluting, coated stents 03 CYPHER Sirolimus-eluting coronary stent FDA approved 2006 Abbott introduces Absorb, a drug eluting bioresorbable vascular scaffold (BVS) made of PLLA 2007 REVA Medical announces trials of its resorbable, radioopaque, drug eluting vascular scaffold made of a new X-ray visible polycarbonate

Early Resorbable stents - Examples Stack et al. 88 Poly(L-lactic acid) stent Yoklavich et al. 96 PLA/TMC stent by J&J Cordis molded by Tesco Assoc. Tamai et al. 00 Zigzag helical coil Poly(L-lactic acid) Deployed in humans Biosensors and Guidant Prototype Self-Expanding Stent

Why is it so difficult to design a polymer stent that matches the performance of metal stents Polymer Properties Not usually radio-opaque Low strength & stiffness Poor flexibility Difficult to deform rapidly without damage Tends to creep under continuous load Physical aging and crystallization during storage Metal Properties Radio-opaque High strength and stiffness High flexibility Easily deformable Creep resistant Storage stability

Why is it so difficult to design a polymer stent that matches the performance of metal stents Polymer Properties Not usually radio-opaque Low strength & stiffness Poor flexibility Difficult to deform rapidly without damage Tends to creep under continuous load Physical aging and crystallization during storage Target Polymer Properties Incorporate iodine Poly(BPA carbonate) Redesign the stent Redesign the stent High Tg, strong interchain interactions Amorphous, high Tg

Tyrosine-derived monomers are building blocks for resorbable biomaterials CH 3 HO C OH CH 3 Bisphenol A (BPA) HO I CH 2 CH 2 O C NH CH CH 2 OH I C O O Non-toxic monomer system Polymer libraries of polyarylates, triblock copolymers, polycarbonates Tyrosine-derived polymers degrade exclusively into metabolites, nutrients and components that are classified as GRAS by the FDA R

Increasing the design flexibility The original REVA stent polymers were terpolymers of iodinated DTR, DT, and PEG

Unprecedented freedom in the design of an optimized stent material Pendant Chain E,B,H, O etc Carboxylate (DT) Iodination PEG Cell Adhesion Resorption Visibility Stiffness Stiffness Stiffness Stiffness Cell Adhesion Tyrosine-derived polycarbonates allow for the efficient modification of polymer properties

The problem of design complexity Poly(glycolic acid) Design parameters: molecular weight molecular weight distribution annealing/crystallinity A simple design of about 20 experiments is sufficient to explore the design space of poly(glycolic acid) Poly(x%DTR-co-y%DT-co-z %PEG MW carbonate) Design parameters: overall polymer composition random vs block architecture PEG molecular weight DTR pendent chain A library of over 10,000 discreet compositions, each one with potentially useful, individual properties It is no longer possible to synthesize all potential compositions explore all potential composition

Combinatorial-Computational Approach Kohn, J., W.J. Welsh, and D. Knight., Biomaterials, 2007. 28(29): p. 4171-7"

We can make hundreds of polymers Automated Parallel Synthesis Station up to 192 parallel reactions substantial flexibility in the design of workflows shared user facility is open to potential collaborators

Rapid Screening Immuno-Fluorescence-Assay to detect adsorbed fibrinogen as a screen for thrombogenicity Procedure Coat microwells with polymers Incubate with a single protein solution Detect adsorbed protein with fluorescently labeled antibody Compare the fluorescence signals for multiple polymers within one plate 384- well plate

Screening for fibrinogen adsorption fluorescence signal (% of control) 300 250 200 150 100 50 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 Polymer The screening of 44 polymers with at least 16 repetitive measurements per polymer (704 data points) can be conveniently achieved in two plates and required only about 2 hours of technician work time.!

Gene Expression of Pro-Inflammatory Cytokines as a screening test for inflammation 10.50 10.00 9.50 9.00 8.50 8.00 7.50 7.00 6.50 6.00 5.50 IL-1 beta expression polymer Variation in IL-1beta expression in peritoneal rat macrophages in contact with 72 different polymer surfaces

Effect of PEG on protein adsorption and cell attachment (fibroblasts) 0.45 100 Adsorbed FN (µg/cm?) 0.40 0.35 0.30 0.25 0.20 0.15 Data Linear Fit R 2 = 0.9616 Cell Attachment (%) 80 60 40 * 0.10 0.05 20 * * 0.00 0 2 4 6 8 10 PEG Content (%) 0 0 2 4 6 8 10 PEG Content (%) Protein adsorption (Fibronectin) on surfaces of poly(dte-co-peg carbonate) is reduced by inclusion of PEG Total cell number decreases significantly when the amount of PEG in the polymer reaches 6 Mol%.

Artificial Neural Network (ANN) Input Input Input Input Input Input Input Input Input Any measured parameter or observation Hidden Layer A set of weighed linear regressions or other functions Output Prediction of the model The ANN needs a training set of data to determine the optimum value of the weighing functions in the hidden layer that lead to the closest match between an experimentally determined outcome and the prediction of the model. Thereafter the ANN can make empirical predictions of the outcome when presented with similar data sets.

Computational Models to Predict Protein Adsorption and Cell Growth 48 polymer" were prepared" 24 polymers" were explored" 24 polymers" were never tested" Experimental data were used to train" the computer models" These data were used as inputs to predict protein adsorption and cell growth"

Prediction of the Glass Transition 120.00 100.00 80.00 Tg (deg C) 60.00 40.00 measured predicted 20.00 0.00 0 10 20 30 40 50 60 70 polymer number (arbitrary)

Prediction of Fibrinogen Adsorption 220 170 120 70 measured predicted 20 0 10 20 30 40 50 Polymer (arbitrary number)

Prediction of Normalized Metabolic Activity (NMA) for rat lung fibroblasts 120 100 80 60 40 measured predicted 20 0 10 20 30 40 50 Polymer (arbitrary number)

Combinatorial-computational method Advantages Relatively simple Relatively cheap Relatively effective for exploring a limited range of properties Disadvantages Requires a training set, e.g., polymers still have to be synthesized and experimental data must be collected Accuracy of the predictions depends on the quality of the experimental data Predictions are only made for specific polymers classes and are not generalizable to other polymer structures

Summary: Acceleration of the pace of development The process started with the identification of desirable polymer properties by the customer, a stent company Searching within a library space of over 10,000 possible compositions, a polymer with suitable properties relating to DEGRADATION, MECHANICAL STENGTH, HEMOCOMPATIBILITY, and X RAY VISIBILITY was found, synthesized and tested within about 1 year The combinatorially designed material performed as predicted. A fully deployable stent could be fabricated upon first trial Visibility by fluoroscopy of the polymer stent (top) and a market leading steel stent (bottom) Hemocompatibility in the pig coronary model: 3 weeks post implantation, there was no evidence for necrosis, inflammation, thrombosis or restenosis.

The initial stent prototype could be deployed (*) Note: This is a historic image, dating back to 2002. This is not representative of the current REVA stent design.

Why is the development of a degradable polymer stent a significant challenge? Polymers lack strength compared to metals, requiring significant optimization of composition and processing Many common polymer properties are incompatible with stent requirements, requiring device design work-arounds : Rapid deformation Device flexibility Extremely thin struts Radio-opacity Vascular tissue compatibility and very benign degradation products to minimize inflammation-mediated restenosis Processibility

Thank you!